Prime Editing for Human Gene Therapy: Where Are We Now?
Cells · 07.02.2023 · 12 (4) · 536
DOI: 10.3390/cells12040536 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 07.02.2023. Verfasst von Kelly Godbout und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC G1V 4G2, Canada. Hauptthemen laut MEDLINE: Gene Editing, Cystic Fibrosis. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, the Canadian Institute of Health Research (CIHR).
Abstract (Originalsprache)
Gene therapy holds tremendous potential in the treatment of inherited diseases. Unlike traditional medicines, which only treat the symptoms, gene therapy has the potential to cure the disease by addressing the root of the problem: genetic mutations. The discovery of CRISPR/Cas9 in 2012 paved the way for the development of those therapies. Improvement of this system led to the recent development of an outstanding technology called prime editing. This system can introduce targeted insertions, deletions, and all 12 possible base-to-base conversions in the human genome. Since the first publication on prime editing in 2019, groups all around the world have worked on this promising technology to develop a treatment for genetic diseases. To date, prime editing has been attempted in preclinical studies for liver, eye, skin, muscular, and neurodegenerative hereditary diseases, in addition to cystic fibrosis, beta-thalassemia, X-linked severe combined immunodeficiency, and cancer. In this review, we portrayed where we are now on prime editing for human gene therapy and outlined the best strategies for correcting pathogenic mutations by prime editing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC G1V 4G2, Canada.
- Department of Molecular Medicine, Faculty of Medicine, Laval University, Quebec City, QC G1V 0A6, Canada.
ORCID-Profile: Kelly Godbout, Jacques P Tremblay
Förderung
- CIHR
- the Canadian Institute of Health Research (CIHR)
Zitieren
APA
Godbout, K., & Tremblay, J. P. (2023). Prime Editing for Human Gene Therapy: Where Are We Now?. Cells, 12(4), 536. https://doi.org/10.3390/cells12040536
Vancouver
Godbout K, Tremblay JP. Prime Editing for Human Gene Therapy: Where Are We Now?. Cells. 2023;12(4):536. doi:10.3390/cells12040536
BibTeX
@article{Godbout2023,
author = {Godbout, Kelly and Tremblay, Jacques P},
title = {Prime Editing for Human Gene Therapy: Where Are We Now?},
journal = {Cells},
year = {2023},
volume = {12},
number = {4},
pages = {536},
doi = {10.3390/cells12040536}
}
EUVIMED